Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
AVZO-023 follows AVZO-021 into clinical trials.
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
The move follows promising but early data presented at ASCO.
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
